ONWARD Medical Records Sales Increase in the Third Quarter of 2025
ONWARD Medical has announced positive results for the third quarter of 2025, marked by an increase in sales and significant regulatory advancements for its ARC-EX and ARC-IM systems.
According to the company's press release, ONWARD Medical achieved a turnover of 1.7 million euros in the third quarter of 2025. In October, the company raised over 50 million euros in capital, strengthening its financial capacity until the first quarter of 2027. The cash balance as of October 31, 2025, stood at 77.7 million euros. The company also noted increased investor interest, with coverage from five banks recommending the purchase of its shares.
Regulatory Progress and Commercial Achievements
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
ONWARD Medical sold 40 ARC-EX systems during the quarter, thus meeting its commercial targets. In terms of regulation, the company obtained FDA authorization for a global study on ARC-IM and received CE certification for ARC-EX, paving the way for its marketing in Europe for clinical and home use. The company also announced scientific publications in prestigious journals, reinforcing the clinical validation of its technologies.
Future Prospects and Market Expansion
The company is preparing to launch its Empower BP study before the end of the year, aimed at evaluating ARC-IM for managing blood pressure instability in individuals with spinal cord injuries. The American market is expanding with the authorization of home use for ARC-EX. The outlook for 2026 remains positive, supported by the commitment to continue the implants of ARC-IM and ARC-BCI to explore new indications, including improving mobility in cases of spinal injuries and Parkinson's disease.
“We continued to deliver strong commercial execution in Q3, and we achieved several meaningful scientific and regulatory milestones across our technology platforms.”
Commercial traction forte avec 40 systèmes ARC-EX vendus en Q3 et disponibilité dans plus de 60 cliniques US; CE Mark pour l'UE et clearance FDA pour usage à domicile élargissent l'opportunité commerciale; IDE approuvé pour ARC-IM permettant le lancement de l'étude pivot Empower BP; publications scientifiques majeures renforcent le dossier clinique.
Risks mentioned
retards dans les autorisations réglementaires
variations de la demande commerciale
concurrence technologique et concurrentielle
incertitudes liées aux études cliniques et résultats futurs
Opportunities identified
FDA clearance for home use expands US market opportunity
CE Mark enables commercialization in EU and facilitates entry to UK and Switzerland
IDE approval for ARC-IM enables initiation of Empower BP pivotal study
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
